SCHEMBL6690572

SCHEMBL6690572

CCCc1cc(=O)oc2c(C(N)CC)c(OC)c3c(c12)OC(C)(C)C=C3

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 6/20 0.53
▸ CA1 P00915 6/20 0.53
▸ CA7 P43166 6/20 0.53
▸ CA9 Q16790 6/20 0.53
▸ CA13 Q8N1Q1 5/20 0.53
▸ NPSR1 Q6W5P4 5/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ MAPK1 P28482 3/20 0.53
▸ CA2 P00918 2/20 0.53
▸ APAF1 O14727 1/20 0.53
▸ PDE4D Q08499 3/20 0.40
▸ KDM4E B2RXH2 6/20 0.36
▸ MAPT P10636 4/20 0.35
▸ USP2 O75604 2/20 0.35
▸ CYP3A4 P08684 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SLCO1B3 Q9NPD5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6650989 0.89 CA12 (0.55) CA12CA1CA7CA9CA13
SCHEMBL7098347 0.88 CA12 (0.51) CA12CA1CA7CA9CA13
SCHEMBL7151144 0.87 CA12 (0.49) CA12CA1CA7CA9CA13
SCHEMBL6685184 0.87 CA12 (0.51) CA12CA1CA7CA9CA13
SCHEMBL7103733 0.86 ALDH1A1 (0.57) CA12CA1CA7CA9CA13
SCHEMBL6630866 0.81 CA12 (0.58) CA12CA1CA7CA9CA13
SCHEMBL31036121 0.79 CA12 (0.55) CA12CA1CA7CA9CA13
SCHEMBL6679208 0.78 ALDH1A1 (0.52) CA12CA1CA7CA9CA13
SCHEMBL6628817 0.77 ALDH1A1 (0.58) CA12CA1CA7CA9CA13
SCHEMBL7144109 0.77 CA12 (0.51) CA12CA1CA7CA9CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379529-A2 PYRANOCOUMARIN COMPOUNDS AS A NOVEL PHARMACOPHORE WITH ANTI-TB ACTIVITY Sarawak Medichem Pharmaceuticals, Inc. (US) 2004-01-14 — — EP disclosed
US-6670383-B2 Such as 5-(2-hydroxy-ethoxy)-2,2-dimethyl-6-propionyl-10-propyl-2H-pyrano(2,3 -f)chromen-8-one for treatment of Mycobacterium infection, AIDS, and tuburculosis ADVANCED LIFE SCIENCES, INC. 2003-12-30 — — US disclosed
US-20030083369-A1 Pyranocoumarin compounds as a novel pharmacophore with anti-TB activity THE LEADERS BANK 2003-05-01 — — US disclosed
WO-2002074777-A2 PYRANOCOUMARIN COMPOUNDS AS A NOVEL PHARMACOPHORE WITH ANTI-TB ACTIVITY SARAWAK MEDICHEM PHARMACEUTICALS, INC. (US) 2002-09-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083369-A1 Pyranocoumarin compounds as a novel pharmacophore with anti-TB activity BBOX1, CYP51A1, HADHB CA12 4852/4885CA1 4872/4885CA7 3808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback